첫 페이지 › 美股新闻 › 본문

阿斯利康肺癌靶向药泰瑞沙新适应症在中国获批

Aim_yuan 发表于 2024-6-26 15:13:20

202 0 0

　　阿斯利康6月26日宣布，中国国家药品监督管理局于2024年6月18日正式批准泰瑞沙&reg;联合培美曲塞和铂类化疗药物用于具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。

CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.

Down

Favorite

Report

转播